Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Chronic Heart Failure Pricing, Reimbursement, and Access

Payers were originally extremely worried about the potential cost burden of Entresto, however, the level of concern surrounding the drug is currently moderate as physician uptake has been lower than expected.

April 13, 2018

Find out more

Digital Pharma: Are We Nearly There?

$2,995.00

Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, is widely documented.

August 14, 2018

Find out more

Renal Cell Cancer Pricing, Reimbursement, and Access

$2,995.00

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

August 22, 2018

Find out more

Value-Based Reimbursement in the US

$2,995.00

The US healthcare environment has been witnessing a slow albeit continuous shift from volume- to value-based reimbursement over the past couple of decades

August 22, 2018

Find out more

Bladder Cancer Pricing, Reimbursement, and Access

$2,995.00

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.

September 27, 2018

Find out more

Datamonitor Healthcare Strategy: Gene Therapy Pipeline and Portfolio Analysis

$2,995.00

Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advancements in the pipeline that aim to invigorate the field in its second generation

December 8, 2017

Find out more

Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities and Barriers

$2,995.00

Commercialization of modern-day gene therapies is now a reality. Next-generation modalities such as chimeric antigen receptor T-cell (CAR- T) therapies are fully in launch mode in the US, with final approvals having also occurred in the EU.

October 25, 2018

Find out more

First-In-Class Therapies’ Shrinking In-Class Monopolies

$2,995.00

Competition from drugs in the same class (with the same mechanism of action and treating the same disease) presents a clear challenge to a first-in-class market entrant. And the speed with which these competitors arrive impacts market dynamics, commercial strategies, and, increasingly, drug prices. Therapies that enjoy extended monopolies as sole entrants in a particular class have greater commercial flexibility in negotiating with payers. Multiple drugs in the same class give payers better leverage with which to negotiate rebates and discounts with drug companies.

November 15, 2018

Find out more

ISPOR Europe 2018 Whitepaper

$2,995.00

November 23, 2018

Find out more

New Pharma Models for a New Healthcare Era

$2,995.00

This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.

December 20, 2018

Find out more

Biosimilar Commercial Strategies and Tactics

$2,995.00

The challenges faced by biosimilar developers are not unlike those confronting their branded counterparts. First, companies must develop high-quality biosimilars and obtain regulatory approval. Next, they must then navigate the vast array of commercial nuances that exist at the national level in order for their products to be used in the clinical setting.

May 14, 2019

Find out more